Spero Therapeutics, Inc. (SPRO)

Several significant events impacted Spero Therapeutics' stock price in the past six months. Results from the Phase 3 PIVOT-PO trial evaluating Tebipenem HBr were presented at IDWeek in October 2025. Spero Therapeutics reported its Third Quarter 2025 financial results on November 13, 2025. On December 19, 2025, Spero announced GSK had resubmitted the NDA for Tebipenem HBr to the FDA, triggering a $25 million milestone payment. Spero Therapeutics announced its Fourth Quarter and Full Year 2025 financial results on March 26, 2026, reporting a net income of $31.5 million for the fourth quarter of 2025, and a full-year net income of $8.6 million for 2025. The FDA set a PDUFA date of June 18, 2026, for Tebipenem HBr. SPRO's share price increased by 187.46% from March 24, 2025, to March 23, 2026.

There is no information available regarding demand seasonality for Spero Therapeutics, Inc.'s products or services. As a clinical-stage biopharmaceutical company with its lead product candidate, Tebipenem HBr, still under regulatory review, commercial sales have not yet commenced.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for multi-drug resistant bacterial infections and rare diseases, operating within the Biotechnology industry. The company's primary focus is Tebipenem HBr, an investigational oral carbapenem-class antibiotic in Phase 3 development for complicated urinary tract infections. Spero Therapeutics has ceased development of other product candidates to concentrate resources on Tebipenem HBr.

Spero Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and conducts clinical trials in North America and internationally. The company has a licensing agreement with GSK for Tebipenem HBr in all territories except certain Asian territories, where Meiji Seika Pharma Co., Ltd. holds rights.

Information explicitly detailing Spero Therapeutics, Inc.'s brand reputation or specific events that have affected it in the past year is not readily available. The available information primarily focuses on financial performance, product development milestones, and regulatory updates.

Spero Therapeutics' ownership is a mix of institutional, insider, and public/individual investors. Institutional investors hold approximately 25.29% to 37.56% of the company's stock, while insiders own between 5.32% and 11%. Public companies and individual investors hold approximately 61.96% of the stock. Major institutional shareholders include Glaxosmithkline Plc, Pfizer Inc, Vanguard Group Inc, Renaissance Technologies Llc, Alphabet Inc., and others.